Department of Surgery, Kang-Nam St. Mary's Hospital, The Catholic University of Korea
Corresponding Author:
Cho Hyun Park ,Tel: 82-2-590-2727, Fax: 02-595-2992, Email: chpark@catholic.ac.kr
Received: May 30, 2005; Accepted: June 30, 2005.
Share :
ABSTRACT
Currently, standard chemotherapy for the treatment of gastric cancer still remains controversial. However, recent series of meta-analysis of adjuvant chemotherapy have shown a small, but statistically significant reduction in risk of death. Moreover, newly developed chemotherapeutic agents for gastric cancer are reported higher response rate than conventional drugs even in a single drug treatment. Therefore, we are awaiting for the result of well-designed large, prospect clinical trials. In this review, recent studies dealing with the chemotherapy of advanced gastric cancer are summarized. While the efficacy of most treatment regimens is only limited, tailored therapy for patient based on clinico-pathological findings and/or molecular biology can improve the treatment result in the near future.
PDF Links
Full text via DOI 
Download Citation 
